Reply: To PMID 24679845

Affiliations

¹ Division of Rheumatology, Allergy and Clinical Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass. Electronic address: AALONG@mgh.harvard.edu.
² RTI Health Solutions, Research Triangle Park, NC.
³ Genentech, South San Francisco, Calif.
⁴ Children's Hospital Colorado and University of Colorado School of Medicine, Denver, Colo.

Comment

Aidan Long et al. J Allergy Clin Immunol. 2015 Jan.

. 2015 Jan;135(1):289-90.

doi: 10.1016/j.jaci.2014.09.018. Epub 2014 Oct 29.

¹ Division of Rheumatology, Allergy and Clinical Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass. Electronic address: AALONG@mgh.harvard.edu.
² RTI Health Solutions, Research Triangle Park, NC.
³ Genentech, South San Francisco, Calif.
⁴ Children's Hospital Colorado and University of Colorado School of Medicine, Denver, Colo.

No abstract available

Comment on

Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab.
Long A, Rahmaoui A, Rothman KJ, Guinan E, Eisner M, Bradley MS, Iribarren C, Chen H, Carrigan G, Rosén K, Szefler SJ. Long A, et al. J Allergy Clin Immunol. 2014 Sep;134(3):560-567.e4. doi: 10.1016/j.jaci.2014.02.007. Epub 2014 Mar 27. J Allergy Clin Immunol. 2014. PMID: 24679845 Clinical Trial.
EXCELS study results do not rule out potential cancer risk with omalizumab.
Li J, Goulding M, Seymour S, Starke P. Li J, et al. J Allergy Clin Immunol. 2015 Jan;135(1):289. doi: 10.1016/j.jaci.2014.09.017. Epub 2014 Oct 29. J Allergy Clin Immunol. 2015. PMID: 25441294 No abstract available.